Dihexa generates more questions from patients than almost any other peptide I am asked about. The preclinical data is attention-grabbing — described by the original researchers as being “seven orders of magnitude more potent than BDNF” at promoting synaptogenesis. But attention-grabbing preclinical data and clinical evidence are not the same thing, and with Dihexa, the gap between the two is wider than with almost any peptide in common discussion. What I tell the patients I coach is this: proceed with extreme caution, and understand both the potential and the risks before making a decision.
At a Glance
| Property | Detail |
|---|---|
| Type | Synthetic analog of angiotensin IV (N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide) |
| Amino acid count | 2 (Tyr-Ile), capped at both ends; derived from the hexapeptide angiotensin IV |
| Primary mechanism | Proposed HGF/c-Met receptor system activation, synaptogenesis (the key mechanism paper was retracted in 2025) |
| Evidence level | Animal studies only; no published human clinical trials |
| Regulatory status | Research compound; not approved for any indication |
| Route of administration | Oral (crosses blood-brain barrier in rats), SC injection |
| Typical community dose | 5-20 mg oral or 2-5 mg SC once daily, 4-8 week cycles (anecdotal) |
What Is Dihexa?
Dihexa is a synthetic derivative of the hexapeptide angiotensin IV, developed by Dr. Joseph Harding and Dr. Jay Wright at Washington State University. It emerged from research on the angiotensin IV (AngIV) receptor system and its role in cognitive function.
The angiotensin system is best known for its role in blood pressure regulation, but a subset of this system — specifically the AT4 receptor (also known as insulin-regulated aminopeptidase, or IRAP) — has been implicated in cognitive processes including memory formation and retrieval. AngIV, a metabolite of the angiotensin cascade, was the first ligand found to enhance cognitive function through this receptor system.
Dihexa was designed as a metabolically stable, orally bioavailable analog of AngIV that could cross the blood-brain barrier — properties that AngIV itself lacks. However, subsequent research revealed that Dihexa’s primary mechanism of action may not be through the AT4/IRAP receptor at all, but rather through the hepatocyte growth factor (HGF)/c-Met receptor system [2, 3].
Mechanism of Action
Primary Pathways
- HGF/c-Met Activation: The current understanding is that Dihexa’s cognitive effects are primarily mediated through the HGF/c-Met receptor system. HGF (hepatocyte growth factor) is a pleiotropic growth factor that plays roles in cell survival, proliferation, migration, and differentiation. In the brain, HGF/c-Met signaling is involved in neuronal development, survival, and synaptic plasticity. Dihexa appears to act as a potentiator of HGF/c-Met signaling, enhancing the system’s activity rather than directly activating the receptor.
- Synaptogenesis: The most striking finding from the Dihexa research is its ability to promote the formation of new synaptic connections between neurons. In the developing group’s cell culture experiments, Dihexa promoted synaptogenesis at picomolar concentrations [1], a potency that led the researchers to describe it as being extraordinarily active. For context, this is a concentration range where very few bioactive molecules demonstrate measurable effects.
- Neurotrophic Effects: Through the HGF/c-Met pathway, Dihexa appears to exert neurotrophic effects — supporting neuronal survival and function in a manner analogous to (but mechanistically distinct from) BDNF. This has led to interest in its potential application for neurodegenerative conditions, though this remains entirely in the realm of preclinical investigation.
Research Assessment
What the Evidence Shows
| Claimed Effect | Evidence Level | Key Studies | Assessment |
|---|---|---|---|
| Reversal of cognitive deficits (scopolamine and aged rats) | Animal studies | McCoy 2013 [1] | Preliminary; paper carries a 2021 expression of concern |
| HGF/c-Met as the mechanism | Animal and cell studies | Benoist 2014 [2] | Retracted in 2025 |
| Blood-brain barrier penetration and oral activity | Rat pharmacokinetic and behavioural studies | McCoy 2013 [1] | Shown in rats only |
| Memory in an Alzheimer’s mouse model | Animal study (independent group) | Sun 2021 [4] | Preliminary |
In the rat studies, Dihexa reversed scopolamine-induced deficits in Morris water maze learning when given into the brain, by intraperitoneal injection (effective at 0.5 mg/kg, not at 0.05 mg/kg) or orally (2 mg/kg fully reversed the deficit), and 2 mg/kg orally improved the same task in 24-month-old rats [1]. The rats absorbed it orally and it crossed the blood-brain barrier, which are important pharmacokinetic properties for any CNS-active agent. An independent group later reported improved water maze performance and less neuroinflammation in APP/PS1 Alzheimer’s model mice given oral Dihexa [4]. Both papers from the developing group have since been flagged: the 2013 paper carries a 2021 expression of concern, and the 2014 mechanism paper was retracted in 2025 [2].
The in vitro potency data is genuinely remarkable — the concentrations at which Dihexa promotes synaptogenesis are among the lowest reported for any neurotrophic agent. Whether this in vitro potency translates to equivalent in vivo effects at clinically achievable doses is a separate question.
What the Evidence Does Not Show
There are no published human clinical trials of Dihexa for any indication. The human safety profile is essentially unknown beyond limited clinical observation. The long-term effects of exogenous synaptogenesis promotion on brain function, neural circuit stability, and neurological health have not been studied.
The HGF/c-Met system is involved in cell proliferation and is implicated in various cancers (c-Met is a proto-oncogene). The implications of chronically activating this pathway, even partially, have not been evaluated in the context of long-term Dihexa use.
The leap from “promotes synaptogenesis in cell culture” to “improves cognition in humans” involves multiple unvalidated assumptions about dosing, brain penetration, regional specificity, and the relationship between new synapse formation and functional cognitive improvement.
Dosing
For informational purposes only — this summarises doses used in research and practice; it is not a prescription or individual medical advice.
No human dose of Dihexa has ever been studied. It has never been tested in a human trial, and the FDA states that it has identified no human exposure data for it. The doses people use come from community experimentation; for orientation, the 2 mg/kg oral dose that worked in rats [1] scales to roughly 20 mg in a 70 kg adult by standard body-surface conversion. The key mechanism paper (Benoist 2014) has been retracted. Dihexa is not approved anywhere, and it is prohibited in sport.
What people take, according to community compilations: 5-20 mg orally once daily in the morning (Peptide DB’s standard is 8-10 mg), or 2-5 mg by subcutaneous injection once daily, in cycles of 4-8 weeks; a minority run 90 days on and 30 days off. Every one of those numbers is anecdotal. They are listed with their sources in the protocol table, together with the retraction and the failed human trial of its relative fosgonimeton.
The safety caveats below apply to every one of these doses. Nobody has measured what Dihexa does in a human body, and the pathway it is thought to act on, HGF/c-Met, drives the growth of several cancers. Longer cycles mean longer exposure to that unknown.
What People Report: What Works and What Doesn’t
Sources: the aggregated community data set (Peptide Protocol Wiki, 45 reports) and the side-effect lists on Peptide DB. The community data set notes that dihexa reports are more variable and less consistent than for most peptides.
Reported to work
- Vivid dreams, the most consistent effect across users. It suggests something is happening in the brain; it says nothing about cognition.
- Sharper thinking, more creativity and easier verbal expression, in some users.
- Better social awareness, in a smaller subset.
Mixed or unclear
- Cognitive benefit overall. Reports are inconsistent, the doses vary several-fold, and none is blinded.
- Lasting “structural” change after a cycle ends, the reason some run 90-day cycles. This rests on the synaptogenesis claim from a mechanism paper that has since been retracted.
- Combinations with Semax or Cerebrolysin, used by a few experienced users and flagged by Peptide DB for possible overstimulation.
Reported not to work, or disappointing
- No perceptible change at all, in a notable share of users.
- Headaches, the most frequent side effect, especially at the start and at higher doses.
- Anxiety, overstimulation and disturbed sleep, which is why the compilations advise morning dosing.
- The closest human evidence is negative: fosgonimeton, an HGF-system modulator from the same research lineage, missed its endpoints in a 26-week Alzheimer’s trial (Porsteinsson 2025).
What a properly designed trial would need to show: before any efficacy trial, a first-in-human safety and pharmacokinetic study with cancer-relevant monitoring of the c-Met pathway; only then a placebo-controlled trial with standardised cognitive testing in a defined group, such as mild cognitive impairment.
Safety and Side Effects
Known
Due to the absence of formal human studies, the safety profile is essentially undocumented. Clinical observation is too limited to establish a reliable side effect profile. Reports from users (not from controlled studies) mention headaches, elevated blood pressure, and heightened emotional responses.
Theoretical Concerns
The c-Met proto-oncogene question is the most significant theoretical safety concern. HGF/c-Met signaling promotes cell proliferation, and aberrant activation of this pathway is associated with multiple cancer types. Whether the degree of c-Met activation produced by therapeutic doses of Dihexa carries oncological risk is unknown.
The effects of promoting synaptogenesis in an adult brain that has undergone normal synaptic pruning are theoretically unpredictable. Synaptic pruning is a developmentally important process, and indiscriminate synapse formation could, in theory, disrupt established neural circuits rather than enhance them.
Contraindications
History of malignancy or active malignancy (theoretical concern based on c-Met mechanism). Pregnancy and lactation (no data). Neurological conditions involving aberrant neural circuit formation (e.g., epilepsy — theoretical concern about synaptogenesis effects).
Drug and Supplement Interactions
No formal interaction studies exist. Given the HGF/c-Met mechanism, theoretical caution with medications that affect this pathway. Potential interaction with antihypertensive medications given the angiotensin system connections.
Clinical Perspective
I want to be candid about Dihexa: it is not a peptide I recommend to the patients I coach. The preclinical data is fascinating, and I understand why patients are drawn to it — the idea of a peptide that promotes new synaptic connections at remarkably low concentrations is compelling. But the gap between preclinical promise and clinical evidence is wider with Dihexa than with almost any other peptide that patients ask me about.
My concerns are specific:
First, the c-Met proto-oncogene involvement. This is not a trivial concern. c-Met activation is a validated drug target in oncology — pharmaceutical companies spend billions developing c-Met inhibitors for cancer treatment. An agent that activates this same pathway, even partially, deserves substantially more safety investigation before it is used chronically in healthy individuals seeking cognitive enhancement.
Second, the absence of any published human data. Even BPC-157, the most-used of these peptides, has only 30 people in three uncontrolled human studies (PMID 42885452). With Dihexa, we have a handful of rat studies and a mechanism of action that raises legitimate safety questions.
Third, the quality and sourcing issue is particularly acute with Dihexa. Because it is available only as a research compound, quality assurance is minimal. Patients are injecting or ingesting material from unregulated sources with no guarantee of purity or accurate dosing.
What I tell patients who ask about Dihexa is this: the science is interesting, but “interesting science” and “ready for clinical use” are different categories. This is a peptide that I will reconsider when human clinical trial data becomes available. Until then, there are better-characterized options for cognitive support.
References
- McCoy AT, Benoist CC, Wright JW, et al. Evaluation of metabolically stabilized angiotensin IV analogs as procognitive/antidementia agents. J Pharmacol Exp Ther. 2013;344(1):141-154. PMID 23055539 (expression of concern 2021, PMID 34551989).
- Benoist CC, Kawas LH, Zhu M, et al. The procognitive and synaptogenic effects of angiotensin IV-derived peptides are dependent on activation of the hepatocyte growth factor/c-met system. J Pharmacol Exp Ther. 2014. PMID 25187433. Retracted 2025 (retraction notice, PMID 40312093).
- Wright JW, Harding JW. The brain hepatocyte growth factor/c-Met receptor system: a new target for the treatment of Alzheimer’s disease. J Alzheimers Dis. 2015;45(4):985-1000. PMID 25649658
- Sun X, Deng Y, Fu X, et al. AngIV-analog Dihexa rescues cognitive impairment and recovers memory in the APP/PS1 mouse via the PI3K/AKT signaling pathway. Brain Sci. 2021;11(11):1487. PMID 34827486
- Porsteinsson AP, et al. Fosgonimeton in mild-to-moderate Alzheimer’s disease (LIFT-AD). J Alzheimers Dis Rep. 2025. PMID 41393340
Disclaimer: This peptide profile is intended for educational purposes. Dihexa is a research compound not approved for human therapeutic use by any regulatory agency. The safety profile in humans is unknown. Consult a qualified physician before pursuing any peptide therapy.
